Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$111.25

-0.489 (-0.44%)

, TOT

Total

$56.20

0.48 (0.86%)

10:19
02/13/18
02/13
10:19
02/13/18
10:19

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JPM

JPMorgan

$111.25

-0.489 (-0.44%)

TOT

Total

$56.20

0.48 (0.86%)

CELG

Celgene

$91.51

-1 (-1.08%)

DGX

Quest Diagnostics

$100.25

1.18 (1.19%)

BA

Boeing

$342.21

-1.59 (-0.46%)

  • 16

    Feb

  • 17

    Feb

  • 21

    Feb

  • 21

    Feb

  • 27

    Feb

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 13

    Mar

  • 25

    Mar

  • 13

    Apr

  • 30

    May

  • 13

    Jul

  • 12

    Oct

JPM JPMorgan
$111.25

-0.489 (-0.44%)

02/13/18
KBWI
02/13/18
UPGRADE
Target $127
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded JPMorgan to Outperform with an unchanged price target of $127. The analyst views the recent pullback in the shares as a buying opportunity.
02/05/18
BERN
02/05/18
NO CHANGE
BERN
More pronounced risks to drug supply chain from Amazon coalition, says Bernstein
Bernstein analyst Lance Wilkes thinks the risks to the drug supply chain from Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) healthcare joint venture are much more pronounced than risks to traditional MCOs. The analyst thinks the coalition could acquire a transparency PBM, effectively creating an employer PBM Co-op.
02/05/18
BWSF
02/05/18
NO CHANGE
Target $194
BWSF
Sell
LendingTree lost JPMorgan as mortgage lending customer, says BWS Financial
BWS Financial analyst Hamed Khorsand reports that LendingTree (TREE) has lost JPMorgan Chase (JPM) as a mortgage lending customer, calling it the company's second "high-profile" mortgage lender loss in about a quarter. The loss of JPMorgan matters both because of how many loans it originates but also due to the read-through that the loss has on the concept of LendingTree's calling center adding value for the lender, according to Khorsand, who keeps a Sell rating and $194 price target on LendingTree shares.
02/12/18
KBWI
02/12/18
UPGRADE
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
TOT Total
$56.20

0.48 (0.86%)

02/09/18
BERN
02/09/18
UPGRADE
Target $66
BERN
Outperform
Total upgraded to Outperform from Market Perform at Bernstein
Bernstein analyst Oswald Clint upgraded Total to Outperform from Market Perform and raised his price target on the stock to $66 from $59, as he believes the company is back to volume growth along with its peers. Clint thinks the company's 5.5% dividend yield, $5B buyback and newly announced plan for 10% dividend growth to 2020 creates a compelling potential for total shareholder returns, he tells investors.
02/01/18
GSCO
02/01/18
UPGRADE
GSCO
Neutral
Statoil upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Michele Della Vigna upgraded Statoil (STO) to Neutral citing the company's leverage to high oil prices. The analyst also moved his coverage of the European Integrated Oils to Attractive from Neutral. His top picks are Total (TOT), Royal Dutch Shell (RDS.A) and Eni SpA (E).
02/13/18
MSCO
02/13/18
UPGRADE
MSCO
Overweight
Total upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Martijn Rats upgraded Total to Overweight while lowering his price target for the shares to EUR 55.60 from EUR 56.
02/13/18
RAJA
02/13/18
UPGRADE
RAJA
Strong Buy
Total upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Jean-Pierre Dmirdjian upgraded total following "robust" Q4 results saying the company continues to demonstrate consistent delivery across the group with a strong cash flow outlook combined with record-low gearing leading to an attractive shareholder return policy and visibility.
CELG Celgene
$91.51

-1 (-1.08%)

01/24/18
LEHM
01/24/18
DOWNGRADE
Target $87
LEHM
Equal Weight
Juno Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Juno Therapeutics (JUNO) to Equal Weight following the proposed acquisition by Celgene (CELG). The analyst believes the offer price of $87 per share fully reflects the value of the stock and sees a low probability of other companies trying to outbid the price. She raised her price target for Juno shares to $87 from $55.
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.
02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
DGX Quest Diagnostics
$100.25

1.18 (1.19%)

02/01/18
PIPR
02/01/18
NO CHANGE
Target $110
PIPR
Neutral
Quest Diagnostics selling off on 'messy' 2018 outlook, says Piper Jaffray
Piper Jaffray analyst William Quirk attributes the post-earnings weakness today in shares of Quest Diagnostics to a "messy" outlook for 2018. The guidance reads as lower revenue growth, but higher earnings, Quirk tells investors in a research note. He believes the 4%-5% revenue growth is reasonable with the legal resolution for the Protecting Access to Medicare Act coming as soon as mid-year. Quirk raised his price target for Quest shares to $110 and keeps a Neutral rating on the name. The analyst finds the shares fairly valued relative to the company's growth rate.
02/02/18
FBCO
02/02/18
INITIATION
Target $107
FBCO
Neutral
Quest Diagnostics assumed with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice assumed coverage of Quest Diagnostics with a Neutral rating and edged up the firm's price target on the stock to $107 from $104 after its Q4 report came in broadly in-line with expectations.
02/13/18
FBCO
02/13/18
UPGRADE
FBCO
Outperform
Quest Diagnostics upgraded to Outperform from Neutral at Credit Suisse
02/13/18
FBCO
02/13/18
UPGRADE
Target $118
FBCO
Outperform
Quest Diagnostics upgraded to Outperform with $118 target at Credit Suisse
Credit Suisse analyst A.J. Rice upgraded Quest Diagnostics to Outperform from Neutral and raised his price target for the shares to $118 from $107. The analyst believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. Quest also has an active retail initiative with Safeway and WalMart, Rice tells investors in a research note.
BA Boeing
$342.21

-1.59 (-0.46%)

02/13/18
EDJN
02/13/18
UPGRADE
EDJN
Buy
Boeing upgraded to Buy from Hold at Edward Jones
02/05/18
JEFF
02/05/18
NO CHANGE
Target $400
JEFF
Buy
Boeing price target raised to $400 from $339 at Jefferies
Jefferies analyst Sheila Kahyaoglu raised her price target for Boeing to $400 saying ramping commercial production rates, productivity gains and a lower tax rate, should drive free cash flow higher through the end of the decade. The analyst believes Boeing's free cash flow could reach over $27 per share by 2020. She keeps a Buy rating on the shares.
02/01/18
WELS
02/01/18
NO CHANGE
Target $365
WELS
Market Perform
Boeing price target raised to $365 from $330 at Wells Fargo
Wells Fargo analyst Sam Pearlstein raised his price target for Boeing to $365 from $330 after the company reported "strong" Q4 results and 2018 free cash flow outlook. The analyst reiterates a Market Perform rating on the shares.
02/01/18
FBCO
02/01/18
NO CHANGE
Target $443
FBCO
Outperform
Boeing price target raised to $443 from $375 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Boeing to $443 from $375 saying the company has become the premier cash flow story within Aerospace and Defense. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.27

0.0027 (1.02%)

17:43
02/23/18
02/23
17:43
02/23/18
17:43
Hot Stocks
Gabriele Cerrone reports 7.0% stake in ContraVir Pharma, may seek board changes »

The shares of common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

17:41
02/23/18
02/23
17:41
02/23/18
17:41
Periodicals
VW settles U.S. diesel suit just before trial, Reuters reports »

Volkswagen's U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$153.99

3.2 (2.12%)

17:40
02/23/18
02/23
17:40
02/23/18
17:40
Hot Stocks
Breaking Hot Stocks news story on IAC »

Barry Diller reports 8.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SPG

Simon Property

$156.66

2.63 (1.71%)

17:37
02/23/18
02/23
17:37
02/23/18
17:37
Syndicate
Breaking Syndicate news story on Simon Property »

Simon Property files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$28.64

0.99 (3.58%)

17:35
02/23/18
02/23
17:35
02/23/18
17:35
Hot Stocks
Fabrinet director Frank Levinson buys 10,000 shares of company stock »

Frank Levinson, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 12

    Mar

  • 29

    Mar

CASI

Casi Pharmaceuticals

$3.85

0.1 (2.67%)

17:33
02/23/18
02/23
17:33
02/23/18
17:33
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

, TNDM

TNDM

17:31
02/23/18
02/23
17:31
02/23/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Dexcom, TNDM »

DexCom reports 5.6%…

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

TNDM

TNDM

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

IDXX

Idexx Laboratories

$187.61

3.75 (2.04%)

17:24
02/23/18
02/23
17:24
02/23/18
17:24
Hot Stocks
Idexx Laboratories director sells 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

CYDY

CytoDyn

$0.72

0.02 (2.86%)

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Syndicate
Breaking Syndicate news story on CytoDyn »

CytoDyn files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRUS

Merus

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Merus »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

MSG

Madison Square Garden

$231.97

2.41 (1.05%)

17:19
02/23/18
02/23
17:19
02/23/18
17:19
Hot Stocks
Silver Lake reports 4.9% stake in Madison Square Garden, may seek talks »

Silver Lake are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,121.90

14.9 (1.35%)

17:12
02/23/18
02/23
17:12
02/23/18
17:12
Syndicate
Breaking Syndicate news story on Markel »

Markel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

17:08
02/23/18
02/23
17:08
02/23/18
17:08
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$162.09

2.69 (1.69%)

, MYL

Mylan

$41.45

0.17 (0.41%)

17:04
02/23/18
02/23
17:04
02/23/18
17:04
Periodicals
PTAB denies Allergan's bid to dismiss restasis patent challenge, Bloomberg says »

Allergan's (AGN)…

AGN

Allergan

$162.09

2.69 (1.69%)

MYL

Mylan

$41.45

0.17 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 19

    Mar

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

SCHW

Charles Schwab

$52.74

0.71 (1.36%)

17:03
02/23/18
02/23
17:03
02/23/18
17:03
Hot Stocks
Charles Schwab appoints Joseph Martinetto as COO of the firm »

On February 22, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

, BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Kraft Heinz announces retirement of Warren Buffett from Board of Directors »

The Kraft Heinz Company…

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

BUD

AB InBev

$107.25

1.91 (1.81%)

QSR

Restaurant Brands

$59.46

1.02 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

SWX

Southwest Gas

$69.17

1.65 (2.44%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Southwest Gas increases quarterly common stock dividend »

The board for Southwest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MS

Morgan Stanley

$56.07

1.21 (2.21%)

, AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

16:56
02/23/18
02/23
16:56
02/23/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Applied Optoelectronics »

Morgan Stanley reports…

MS

Morgan Stanley

$56.07

1.21 (2.21%)

AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.